

## REMARKS

Applicants respectfully submit that the final rejection asserted by the Examiner in the Office Action mailed January 28, 2003 was premature and finality should be withdrawn. Further, Applicants request that the claim amendments submitted in Applicants' Reply of April 28, 2003 be entered and the arguments considered.

### Status of Amendments

The claim amendments submitted in Applicants' Reply of April 28, 2003 have not been entered.

Applicants note that claim 7 was inadvertently unamended in Applicants' Reply and remained dependent from claim 5, a claim proposed to be canceled. The Examiner pointed out this oversight in the Advisory Action mailed July 7, 2003. In a subsequent telephonic interview with the attorney of record, the Examiner refused to enter an amendment correcting the dependency of claim 7. Because of this improper dependency, the Examiner asserted that the other amendments contained in Applicants' Reply were not entered, nor were Applicants' remarks in the Reply considered. A Supplemental Amendment correcting the dependency of claim 7 will be promptly filed should the amendments in Applicants' Reply of April 28, 2003, be entered.

### Claims Under Examination in the Final Office Action Mailed January 28, 2003

Claim 1, the sole independent claim under examination, was amended in Applicants' Reply mailed June 6, 2002. The amendment was entered and examined, resulting in the Final Office Action mailed January 28, 2003. Claim 1 was amended in Applicants' Reply of June 6, 2003, as follows:

1. A pharmaceutical composition comprising as an active ingredient a recombinant polyclonal antibody capable of reacting with or binding to proteins or epitopes derived from an inhaled, ingested, or airborne [[an]] allergen, together with one or more ~~pharmaceutical~~ pharmaceutically acceptable excipients.

### Legal Standard for Final Rejections

Applicants respectfully submit that the rejection set forth in the Final Office Action mailed January 28, 2003 was prematurely made final. The M.P.E.P. § 706.07(a) sets forth the analytical framework for properly entering a final rejection. This section states (emphasis added):

Under present practice, second or any subsequent action on the merits shall be final, except where the examiner introduces a new ground of rejection that is neither necessitated by applicant's amendment of the claims nor based on information submitted in an information disclosure statement filed during the period set in 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p).

\*\*\*\*\*

A second or any subsequent action on the merits in any application ... should not be made final if it includes a rejection, on prior art not of record, of any claim amended to include limitations which should reasonably have been expected to be claimed.

Thus, the M.P.E.P. § 706.07(a) provides circumstances in which a second or subsequent action should not be made final. Applicants submit that the facts of the present case satisfy both of the above-identified exceptions and that satisfying either of the exceptions is sufficient to properly withdraw the finality of the Office Action mailed January 28, 2003.

### The New Ground of Rejection Not Necessitated by Applicants' Amendment

The Examiner asserts, in the Final Office Action mailed January 28, 2003, that the new ground of rejection was necessitated by the amendment filed in Applicants' Reply mailed June 6, 2002. All pending claims were thus finally rejected, under 35 U.S.C. § 103(a), over U.S. Patent No. 4,740,371 (newly cited; "the '371 patent"), in view of U.S. Patent No. 5,789,208 (art of record; "the '208 patent").

Applicants respectfully submit that the newly asserted obviousness rejection was

not necessitated by Applicants' amendment for two distinct reasons. First, the amendment served to narrow the scope of the claimed invention. Prior to the amendment, the claimed pharmaceutical composition contained "as an active ingredient a recombinant polyclonal antibody capable of reacting with or binding to [any] allergen." The amendment reduced the recombinant polyclonal antibodies to those that are capable reacting with or binding to "proteins or epitopes derived from inhaled, ingested, or airborne allergen." Thus, any rejection for obviousness that may be asserted against the more narrow claim could properly have been asserted against the broader claim.

Second, the newly cited art is not relevant to the subject matter of the amendment. The Examiner characterizes the newly cited '371 patent as teaching

pharmaceutical compositions of IgG polyclonal antibody or mixtures of antibody classes for the treatment of allergies wherein said polyclonal antibodies are human, complexed with negatively or positively charged excipients, are 100% target specific, do not elicit an anaphylactic response in humans, do not cross react with self antigens in a patient are given in a concentration with sufficient density to mediate the elimination of an allergen from a patient, are formulated for topical nasal administration, are free of the allergen to which the antibody is reactive (see specifically column 8, lines 15-33, in particular), are provided as a solution and wherein the allergen is derived from house dust mites in the range of 1 $\mu$ g to 1g per unit dosage form. *Final Office Action* mailed January 28, 2003, paragraph bridging pages 2-3.

In making the obviousness rejection based on the '371 patent, the Examiner states that

[o]ne of ordinary skill in the art ... would have been motivated to substitute recombinant polyclonal antibodies taught by the '208 patent for conventional polyclonal antibodies as taught by the '371 patent for treating allergies. *Final Office Action* mailed January 28, 2003, page 3, second paragraph.

Nothing in the Examiner's treatment of the '371 patent addresses Applicants' amendment regarding "proteins or epitopes derived from inhaled, ingested, or airborne allergen." Accordingly, the Examiner's characterization of the '371 patent and the newly asserted rejection does not distinguish between the antibodies encompassed by the unamended claims compared to the claims as amended in Applicants' Reply mailed June 6, 2002.

The '371 patent and the rejection therefore could have properly been asserted in the previous, non-final Office Action but was not.

Because this new rejection was neither asserted in the previous Office Action nor necessitated by Applicants amendment, the finality of the Office Action mailed January 28, 2003 is premature and should be withdrawn.

#### The Amendments Should Have Been Reasonably Expected

Even accepting, *arguendo*, that the newly asserted obviousness rejection in view of the '371 patent was necessitated by Applicants' amendment, the Examiner should reasonably have expected such an amendment, making finality of the rejection improper. M.P.E.P. § 706.07(a). The Examiner, in the non-final Office Action mailed March 7, 2002, rejected claims 1, 5, and 9-12 under 35 U.S.C. § 102(b) in view of the '208 patent. In relevant part, the Examiner characterized the '208 patent disclosing pharmaceutical compositions of polyclonal antibodies that satisfied every limitation of the instant claims.

As noted in Applicants' Reply of June 6, 2002, the '208 patent teaches pharmaceutical compositions containing antibodies that recognize tumor-specific antigens for the treatment of cancer. By contrast, Applicants' invention is used for the treatment of allergies and allergic reaction. Accordingly, claim 1 was amended to limit the types of antibodies encompassed by the claims to only those antibodies that react with or bind to proteins or epitopes derived from an inhaled, ingested, or airborne allergen. This amendment effectively removed the pharmaceutical compositions of the '208 patent from within the scope of Applicants' claims because the antibodies of the '208 patent recognize tumor-specific proteins or epitopes, not ones derived from inhaled, ingested, or airborne allergens.

The Examiner should have reasonably expected such a claim amendment. The present application is entitled "Polyclonal Antibody Composition for Treating Allergy" (emphasis added). And, in describing the allergic responses suitable for treatment using the methods and compositions of the invention, Applicants point out that "the allergens

enter the body of a patient through inhalation, ingestion, or through the skin”  
(Specification, page 3, lines 14-16). The specification, when read in its entirety, makes clear that Applicants invention is directed to the treatment of allergies. Accordingly, in view of the ‘208 patent, the Examiner should have reasonably expected Applicants to amend the claim 1 in a manner that excludes the treatment of cancer. For this reason alone, finality of the January 28, 2003 Office Action is premature and should be removed.

CONCLUSION

Applicants respectfully submit that the finality of new rejection asserted in the Office Action mailed January 28, 2003 was premature and should be removed. No fee is believed due in connection with this Petition. However, if there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

*July 24, 2003*

*Kristina Bieker-Brady*

Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045